|
|
Article: New cancer drug linked to hand-foot syndrome: sorafenib is used off label for melanoma.(Clinical Rounds)
- Article from:
- Skin & Allergy News
- Article date:
- February 1, 2007
- Author:
-
|
Copyright informationCOPYRIGHT 2007 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
STOWE, VT. -- A "striking" erythematous, peeling eruption of the distal extremities associated with a new cancer drug will be seen increasingly in dermatologists' offices, Dr. Peter W. Heald predicted at a dermatology conference sponsored by the University of Vermont.
The drug, sorafenib, was approved in 2005 for the treatment of advanced renal cell carcinoma. Codeveloped by Bayer Pharmaceuticals and Onyx Pharmaceuticals Inc. under the name Nexavar, the agent is a multikinase inhibitor of tumor-cell proliferation and angiogenesis. It is currently being evaluated for a variety of other tumors, including melanoma.
Meanwhile, some dermatology patients with advanced ...